Khosrow Kashfi to Cell Line, Tumor
This is a "connection" page, showing publications Khosrow Kashfi has written about Cell Line, Tumor.
Connection Strength
1.154
-
Chattopadhyay M, Nath N, Kodela R, Metkar S, Soyemi SA, Kashfi K. NOSH-aspirin (NBS-1120) inhibits estrogen receptor-negative breast cancer in?vitro and in?vivo by modulating redox-sensitive signaling pathways. J Pharmacol Exp Ther. 2025 Jan; 392(1):100019.
Score: 0.135
-
Chattopadhyay M, Kodela R, Santiago G, Le TTC, Nath N, Kashfi K. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-?B, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 06; 176:113857.
Score: 0.097
-
Vannini F, Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism. Redox Biol. 2015 08; 5:421.
Score: 0.073
-
Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec; 6:318-325.
Score: 0.071
-
Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015 Dec; 6:287-296.
Score: 0.071
-
Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, Kashfi K. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg Med Chem Lett. 2015 Oct 15; 25(20):4677-82.
Score: 0.071
-
Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, Kashfi K. Nitric Oxide-Releasing Aspirin Suppresses NF-?B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. Molecules. 2015 Jul 09; 20(7):12481-99.
Score: 0.071
-
Chattopadhyay M, Nath N, Kodela R, Sobocki T, Metkar S, Gan ZY, Kashfi K. Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates ?-catenin expression. Leuk Res. 2013 Oct; 37(10):1302-8.
Score: 0.062
-
Kashfi K. Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. Antioxid Redox Signal. 2014 Feb 10; 20(5):831-46.
Score: 0.061
-
Nath N, Liu X, Jacobs L, Kashfi K. Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets ?-catenin. Drug Des Devel Ther. 2013; 7:389-96.
Score: 0.061
-
Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012 Mar 15; 83(6):715-22.
Score: 0.055
-
Chattopadhyay M, Kodela R, Nath N, Street CR, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15; 83(6):733-40.
Score: 0.055
-
Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-?B signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15; 83(6):723-32.
Score: 0.055
-
Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, Kashfi K. Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents. Bioorg Med Chem Lett. 2011 Dec 01; 21(23):7146-50.
Score: 0.054
-
Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 2009 Nov 15; 78(10):1298-304.
Score: 0.046
-
Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun. 2007 Jul 13; 358(4):1096-101.
Score: 0.040
-
Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans. 2005 Aug; 33(Pt 4):701-4.
Score: 0.035
-
Tabatabaei Dakhili SA, P?rez DJ, Gopal K, Haque M, Ussher JR, Kashfi K, Vel?zquez-Mart?nez CA. SP1-independent inhibition of FOXM1 by modified thiazolidinediones. Eur J Med Chem. 2021 Jan 01; 209:112902.
Score: 0.025
-
Lee M, McGeer E, Kodela R, Kashfi K, McGeer PL. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct; 61(10):1724-34.
Score: 0.015